These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 17573598)

  • 41. Vets, denialists and rememberers: social typologies of patient adherence and non-adherence to HAART from the perspective of HIV care providers.
    Orchard T; Salters K; Palmer A; Michelow W; Lepik KJ; Hogg R
    AIDS Care; 2015; 27(6):758-61. PubMed ID: 25635938
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predicting and monitoring antiretroviral adherence.
    Gross R
    LDI Issue Brief; 2007; 13(2):1-4. PubMed ID: 18354853
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Highly active antiretroviral therapy adherence and its determinants in selected hospitals from south and central Ethiopia.
    Beyene KA; Gedif T; Gebre-Mariam T; Engidawork E
    Pharmacoepidemiol Drug Saf; 2009 Nov; 18(11):1007-15. PubMed ID: 19650153
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Achieving adherence with antiretroviral medications for pediatric HIV disease.
    Byrne M; Honig J; Jurgrau A; Heffernan SM; Donahue MC
    AIDS Read; 2002 Apr; 12(4):151-54, 161-4. PubMed ID: 12071185
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Knowledge of structured treatment interruption and adherence to antiretroviral therapy.
    Acri T; Coco A; Lin K; Johnson R; Eckert P
    AIDS Patient Care STDS; 2005 Mar; 19(3):167-73. PubMed ID: 15798384
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Electronic monitoring: adherence assessment or intervention?
    Wagner GJ; Ghosh-Dastidar B
    HIV Clin Trials; 2002; 3(1):45-51. PubMed ID: 11819185
    [TBL] [Abstract][Full Text] [Related]  

  • 47. One-year adherence to clinic visits after highly active antiretroviral therapy: a predictor of clinical progress in HIV patients.
    Park WB; Choe PG; Kim SH; Jo JH; Bang JH; Kim HB; Kim NJ; Oh M; Choe KW
    J Intern Med; 2007 Mar; 261(3):268-75. PubMed ID: 17305649
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intricacies and inter-relationships between HIV disclosure and HAART: a qualitative study.
    Klitzman RL; Kirshenbaum SB; Dodge B; Remien RH; Ehrhardt AA; Johnson MO; Kittel LE; Daya S; Morin SF; Kelly J; Lightfoot M; Rotheram-Borus MJ;
    AIDS Care; 2004 Jul; 16(5):628-40. PubMed ID: 15223532
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A measurement model of medication adherence to highly active antiretroviral therapy and its relation to viral load in HIV-positive adults.
    Llabre MM; Weaver KE; Durán RE; Antoni MH; McPherson-Baker S; Schneiderman N
    AIDS Patient Care STDS; 2006 Oct; 20(10):701-11. PubMed ID: 17052140
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA.
    Murphy DA; Wilson CM; Durako SJ; Muenz LR; Belzer M;
    AIDS Care; 2001 Feb; 13(1):27-40. PubMed ID: 11177463
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Better physician-patient relationships are associated with higher reported adherence to antiretroviral therapy in patients with HIV infection.
    Schneider J; Kaplan SH; Greenfield S; Li W; Wilson IB
    J Gen Intern Med; 2004 Nov; 19(11):1096-103. PubMed ID: 15566438
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of pill burden on discontinuation of the initial HAART regimen in minority female patients prescribed 1 pill/day versus any other pill burden.
    Hill S; Kavookjian J; Qian J; Chung A; Vandewaa J
    AIDS Care; 2014; 26(5):595-601. PubMed ID: 24111921
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antiretroviral adherence and pharmacokinetics: review of their roles in sustained virologic suppression.
    Pham PA
    AIDS Patient Care STDS; 2009 Oct; 23(10):803-7. PubMed ID: 19795999
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An investigation of why eligible patients do not receive HAART.
    Maisels L; Steinberg J; Tobias C
    AIDS Patient Care STDS; 2001 Apr; 15(4):185-91. PubMed ID: 11359660
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [How and why should adherence to antiretroviral therapy].
    Knobel H
    Enferm Infecc Microbiol Clin; 2002 Dec; 20(10):481-3. PubMed ID: 12433348
    [No Abstract]   [Full Text] [Related]  

  • 56. Evaluation of adherence to antiretroviral therapy in Italian HIV patients.
    Dorz S; Lazzarini L; Cattelan A; Meneghetti F; Novara C; Concia E; Sica C; Sanavio E
    AIDS Patient Care STDS; 2003 Jan; 17(1):33-41. PubMed ID: 12614518
    [TBL] [Abstract][Full Text] [Related]  

  • 57. HAART with didanosine once versus twice daily: adherence and efficacy.
    Roca B; Lapuebla C; Vidal-Tegedor B
    Int J Infect Dis; 2005 Jul; 9(4):195-200. PubMed ID: 15964537
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Measuring medication adherence: is assessment of missed doses sufficient?
    Wagner GJ; Rabkin JG
    AIDS; 1999 Dec; 13(17):2491-2. PubMed ID: 10597801
    [No Abstract]   [Full Text] [Related]  

  • 59. [Utilization of prescribed drugs by HIV infected individuals: qualitative approach].
    Acurcio FA; Guimarães MD
    Rev Saude Publica; 1999 Feb; 33(1):73-84. PubMed ID: 10436624
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Missed medication doses in rheumatic arthritis patients: intentional and unintentional reasons.
    Lorish CD; Richards B; Brown S
    Arthritis Care Res; 1989 Mar; 2(1):3-9. PubMed ID: 2488121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.